Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas

Glioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could...

Full description

Bibliographic Details
Main Authors: Siliang Chen, Shuxin Zhang, Zhihao Wang, Junhong Li, Yunbo Yuan, Tengfei Li, Mingrong Zuo, Wentao Feng, Wenhao Li, Mina Chen, Yanhui Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1038272/full
_version_ 1811232792823988224
author Siliang Chen
Shuxin Zhang
Shuxin Zhang
Zhihao Wang
Junhong Li
Yunbo Yuan
Tengfei Li
Mingrong Zuo
Wentao Feng
Wenhao Li
Mina Chen
Yanhui Liu
author_facet Siliang Chen
Shuxin Zhang
Shuxin Zhang
Zhihao Wang
Junhong Li
Yunbo Yuan
Tengfei Li
Mingrong Zuo
Wentao Feng
Wenhao Li
Mina Chen
Yanhui Liu
author_sort Siliang Chen
collection DOAJ
description Glioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could regulate malignant biological behaviors and response to immune checkpoint inhibitors in multiple cancers. However, the relationship of purine metabolism with clinicopathological features and the immune landscape of glioma remains unclear. In this study, we explored the relationships between the expression of purine metabolism-related genes (PuMGs) and tumor features, including prognosis and microenvironment of glioma, based on analyses of 1,523 tumors from 4 public databases and our cohort. Consensus clustering based on 136 PuMGs classified the glioma patients into two clusters with significantly distinguished prognosis and immune microenvironment landscapes. Increased immune infiltration was associated with more aggressive gliomas. The prognostic Purine Metabolism-Related Genes Risk Signature (PuMRS), based on 11 critical PuMGs, stratified the patients into PuMRS low- and high-risk groups in the training set and was validated by validation sets from multiple cohorts. The high-risk group presented with significantly shorter overall survival, and further survival analysis demonstrated that the PuMRS was an independent prognostic factor in glioma. The nomogram combining PuMRS and other clinicopathological factors showed satisfactory accuracy in predicting glioma patients’ prognosis. Furthermore, analyses of the tumor immune microenvironment suggested that higher PuMRS was correlated with increased immune cell infiltration and gene expression signatures of “hotˮ tumors. Gliomas in the PuMRS high-risk group presented a higher expression level of multiple immune checkpoints, including PD-1 and PD-L1, and a better-predicted therapy response to immune checkpoint inhibitors. In conclusion, our study elucidated the relationship between the expression level of PuMGs and the aggressiveness of gliomas. Our study also endorsed the application of PuMRS to construct a new robust model for the prognosis evaluation of glioma patients. The correlations between the profiles of PuMGs expression and tumor immune microenvironment potentially provided guidance for immunotherapy in glioma.
first_indexed 2024-04-12T11:09:21Z
format Article
id doaj.art-9abff2a086164bcab2f63d7916dc3f0a
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-04-12T11:09:21Z
publishDate 2022-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-9abff2a086164bcab2f63d7916dc3f0a2022-12-22T03:35:39ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-11-011310.3389/fphar.2022.10382721038272Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomasSiliang Chen0Shuxin Zhang1Shuxin Zhang2Zhihao Wang3Junhong Li4Yunbo Yuan5Tengfei Li6Mingrong Zuo7Wentao Feng8Wenhao Li9Mina Chen10Yanhui Liu11Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Head and Neck Surgery, School of Medicine, Sichuan Cancer Hospital and Institute, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaNeuroscience and Metabolism Research, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaGlioma is the most common malignant tumor in the central nervous system. The impact of metabolism on cancer development and the immune microenvironment landscape has recently gained broad attention. Purines are involved in multiple metabolic pathways. It has been proved that purine metabolism could regulate malignant biological behaviors and response to immune checkpoint inhibitors in multiple cancers. However, the relationship of purine metabolism with clinicopathological features and the immune landscape of glioma remains unclear. In this study, we explored the relationships between the expression of purine metabolism-related genes (PuMGs) and tumor features, including prognosis and microenvironment of glioma, based on analyses of 1,523 tumors from 4 public databases and our cohort. Consensus clustering based on 136 PuMGs classified the glioma patients into two clusters with significantly distinguished prognosis and immune microenvironment landscapes. Increased immune infiltration was associated with more aggressive gliomas. The prognostic Purine Metabolism-Related Genes Risk Signature (PuMRS), based on 11 critical PuMGs, stratified the patients into PuMRS low- and high-risk groups in the training set and was validated by validation sets from multiple cohorts. The high-risk group presented with significantly shorter overall survival, and further survival analysis demonstrated that the PuMRS was an independent prognostic factor in glioma. The nomogram combining PuMRS and other clinicopathological factors showed satisfactory accuracy in predicting glioma patients’ prognosis. Furthermore, analyses of the tumor immune microenvironment suggested that higher PuMRS was correlated with increased immune cell infiltration and gene expression signatures of “hotˮ tumors. Gliomas in the PuMRS high-risk group presented a higher expression level of multiple immune checkpoints, including PD-1 and PD-L1, and a better-predicted therapy response to immune checkpoint inhibitors. In conclusion, our study elucidated the relationship between the expression level of PuMGs and the aggressiveness of gliomas. Our study also endorsed the application of PuMRS to construct a new robust model for the prognosis evaluation of glioma patients. The correlations between the profiles of PuMGs expression and tumor immune microenvironment potentially provided guidance for immunotherapy in glioma.https://www.frontiersin.org/articles/10.3389/fphar.2022.1038272/fullpurine metabolismgliomatumor microenvironmentprognosisimmune infiltrationimmune checkpoint inhibitor
spellingShingle Siliang Chen
Shuxin Zhang
Shuxin Zhang
Zhihao Wang
Junhong Li
Yunbo Yuan
Tengfei Li
Mingrong Zuo
Wentao Feng
Wenhao Li
Mina Chen
Yanhui Liu
Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
Frontiers in Pharmacology
purine metabolism
glioma
tumor microenvironment
prognosis
immune infiltration
immune checkpoint inhibitor
title Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
title_full Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
title_fullStr Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
title_full_unstemmed Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
title_short Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
title_sort purine metabolism related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
topic purine metabolism
glioma
tumor microenvironment
prognosis
immune infiltration
immune checkpoint inhibitor
url https://www.frontiersin.org/articles/10.3389/fphar.2022.1038272/full
work_keys_str_mv AT siliangchen purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT shuxinzhang purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT shuxinzhang purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT zhihaowang purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT junhongli purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT yunboyuan purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT tengfeili purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT mingrongzuo purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT wentaofeng purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT wenhaoli purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT minachen purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas
AT yanhuiliu purinemetabolismrelatedgeneexpressionsignaturepredictssurvivaloutcomeandindicatesimmunemicroenvironmentprofileofgliomas